研報掘金丨華泰證券:杭州銀行業績增速靚麗,維持“增持”評級
華泰證券研報指出,杭州銀行(600926.SH)2024年營收、歸母淨利潤同比+9.6%、+18.1%,增速較前三季度+5.7pct、-0.6pct,公司營收增速提升幅度略超我們預期,利潤增速保持上市銀行第一梯隊,彰顯優異成長性,後續關注可轉債轉股進度,維持“增持”評級。受益於浙江省“千項萬億”基建工程與平急兩用、保障房、園區建設等發展,公司2025年開門紅投放延續高增,且投放較為前置,有利於持續提振營收。當前杭州銀行有135 億元轉債正處於轉股期,若剩餘轉債全部轉股,測算可提升資本充足率1.1pct。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.